Alto Neuroscience, Inc. ("Alto") , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a favorable ...

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX100 to 800 Patients SHIELD II Enrolled more than ...

Introduction Blood and blood products are essential for patients in need of transfusion therapy, especially those undergoing ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Q4 2024 Earnings Call Transcript February 3, 2025 Operator: Good morning, and welcome to the IDEXX Laboratories’ Fourth ...

VANCOUVER, BC / ACCESS Newswire / January 30, 2025 / Guanajuato Silver Company Ltd. (the "Company" or "GSilver") is pleased to announce that a new National Instrument ("NI" ...

Continuing professional development, or CPD, refers to the minimum ongoing education and training requirements necessary for ...

Kim Newcomer, director of volunteers, Colorectal Cancer Alliance, discusses a study conducted with Takeda and the Harris Poll ...

Annual product data found the company's innovative patient affordability solutions achieved these noteworthy successes in 2024: "2024 was a pivotal year for our patient affordability business," said ...

Background Cancer, a major global health challenge, not only threatens lives but also imposes severe financial burdens, known ...